Æterna Zentaris

aeternazentaris.com

Æterna Zentaris Inc.

1405 du Parc-Technologique Blvd.
G1P 4P5 Québec
Canada

Phone

aeternazentaris.com
Profile Products News

About Æterna Zentaris

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy.

Read more about Æterna Zentaris

Advertisement

Revolutionize your production: real-time Raman analysis for maximum efficiency
Revolutionize your production: real-time Raman analysis for maximum efficiency
Efficient inline analysis for liquids and solids
Efficient inline analysis for liquids and solids
User-friendly software for effortless Design of Experiments (DoE)
User-friendly software for effortless Design of Experiments (DoE)

Product portfolio of Æterna Zentaris

Product portfolio

Show all

News about Æterna Zentaris

Æterna Zentaris

01-Jul-2010 | research and development

Aeterna Zentaris Receives Positive Scientific Advice for its Phase 3 Trial with Perifosine in Colorectal Cancer

Aeterna Zentaris Inc. announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) regarding the Phase 3 trial ...

Read news
Æterna Zentaris

11-Jun-2010 | research and development

Aeterna Zentaris Reports Final Results of a Phase 2 Study of Perifosine in the Treatment of Colorectal Cancer

Aeterna Zentaris Inc. reported final results on the clinical activity of perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral ...

Read news
Æterna Zentaris

20-May-2010 | research and development

Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for Treatment of Ovarian Cancer

Aeterna Zentaris Inc. announced that it has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal ...

Read news
Æterna Zentaris

11-May-2010 | research and development

Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer

Aeterna Zentaris Inc. announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation for AEZS-108, its ...

Read news
Æterna Zentaris

12-Apr-2010 | research and development

Aeterna Zentaris Announces Initiation of Phase 3 Registration Trial with Perifosine in Refractory Advanced Colorectal Cancer

Æterna Zentaris Inc. announced the initiation of a Phase 3 registration clinical trial with perifosine (KRX-0401), the Company's potentially first-in-class ...

Read news
Æterna Zentaris

07-Apr-2010 | research and development

Æterna Zentaris Announces Perifosine Receives FDA Fast Track Designation for Treatment of Refractory Advanced Colorectal Cancer

Æterna Zentaris Inc. announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for ...

Read news
Æterna Zentaris

26-Nov-2009 | research and development

Æterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108

Æterna Zentaris Inc. announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in ...

Read news
Æterna Zentaris

24-Sep-2009 | research and development

Æterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer

Æterna Zentaris Inc. announced the completion of a Phase 1 study of its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in ...

Read news
Show more news about Æterna Zentaris

Here you will find Æterna Zentaris Inc.